Literature DB >> 23452038

Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.

Aditya Raghunathan1, Khalida Wani, Terri S Armstrong, Elizabeth Vera-Bolanos, Maryam Fouladi, Richard Gilbertson, Amar Gajjar, Stewart Goldman, Norman L Lehman, Phillipe Metellus, Tom Mikkelsen, Mary Jo T Necesito-Reyes, Antonio Omuro, Roger J Packer, Sonia Partap, Ian F Pollack, Michael D Prados, H Ian Robins, Riccardo Soffietti, Jing Wu, C Ryan Miller, Mark R Gilbert, Kenneth D Aldape.   

Abstract

Ependymomas originate in posterior fossa (PF), supratentorial (ST) or spinal cord (SC) compartments. At present, grading schemes are applied independent of anatomic site. We performed detailed histological examination on 238 World Health Organization grade II and III ependymomas. Among PF ependymomas, the presence of hypercellular areas, necrosis, microvascular proliferation and elevated mitotic rate (all P < 0.01) were significantly associated with worse progression-free survival (PFS), while extensive ependymal canal formation was not (P = 0.89). Similar to the PF tumors, microvascular proliferation (P = 0.01) and elevated mitotic rate (P = 0.03) were significantly associated with worse PFS in the ST tumors. However, in contrast to PF tumors, extensive ependymal canals (P = 0.03) were associated with worse clinical outcome in ST ependymomas, but hypercellularity (P = 0.57) and necrosis (P = 0.47) were not. On multivariate Cox regression, after adjusting for relevant clinical variables, individual histological factors and a composite histological score remained significant among ST and PF ependymoma. In contrast to both PF and ST ependymoma, histological features were not found to be associated with PFS in SC tumors. Taken together, the clinical relevance of specific histological features in ependymoma appears to be related to the anatomic site of origin and suggests that site-specific grading criteria be considered in future classification systems.
© 2013 International Society of Neuropathology.

Entities:  

Keywords:  ependymoma; histology; progression-free survival

Mesh:

Year:  2013        PMID: 23452038     DOI: 10.1111/bpa.12050

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  21 in total

1.  Prognostic marker analysis in pediatric intracranial ependymomas.

Authors:  Roger E McLendon; Eric Lipp; Diane Satterfield; Melissa Ehinger; Alan Austin; Debra Fleming; Kathryn Perkinson; Michaela Lefaivre; David Zagzag; Benjamin Wiener; Sri Gururangan; Herbert Fuchs; Henry S Friedman; James E Herndon; Patrick Healy
Journal:  J Neurooncol       Date:  2015-01-07       Impact factor: 4.130

2.  Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients.

Authors:  Elizabeth Vera-Bolanos; Kenneth Aldape; Ying Yuan; Jimin Wu; Khalida Wani; Mary Jo Necesito-Reyes; Howard Colman; Girish Dhall; Frank S Lieberman; Philippe Metellus; Tom Mikkelsen; Antonio Omuro; Sonia Partap; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Mark R Gilbert; Terri S Armstrong
Journal:  Neuro Oncol       Date:  2014-08-13       Impact factor: 12.300

Review 3.  Understanding Ependymoma Oncogenesis: an Update on Recent Molecular Advances and Current Perspectives.

Authors:  Kirti Gupta; Pravin Salunke
Journal:  Mol Neurobiol       Date:  2015-12-28       Impact factor: 5.590

4.  Evaluation of chromosome 1q gain in intracranial ependymomas.

Authors:  Madhu Rajeshwari; Mehar Chand Sharma; Aanchal Kakkar; Aruna Nambirajan; Vaishali Suri; Chitra Sarkar; Manmohan Singh; Ravindra Kumar Saran; Rakesh Kumar Gupta
Journal:  J Neurooncol       Date:  2016-01-02       Impact factor: 4.130

Review 5.  Spinal cord ependymoma: a review of the literature and case series of ten patients.

Authors:  Emma Celano; Arsalaan Salehani; James G Malcolm; Erik Reinertsen; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2016-05-06       Impact factor: 4.130

6.  Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours.

Authors:  Malak S Abedalthagafi; Michael P Wu; Parker H Merrill; Ziming Du; Terri Woo; Shu-Hsien Sheu; Shelley Hurwitz; Keith L Ligon; Sandro Santagata
Journal:  J Pathol       Date:  2016-03       Impact factor: 7.996

Review 7.  Posterior fossa tumors in children: developmental anatomy and diagnostic imaging.

Authors:  Charles Raybaud; Vijay Ramaswamy; Michael D Taylor; Suzanne Laughlin
Journal:  Childs Nerv Syst       Date:  2015-09-09       Impact factor: 1.475

Review 8.  Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.

Authors:  Amy K LeBlanc; Christina Mazcko; Diane E Brown; Jennifer W Koehler; Andrew D Miller; C Ryan Miller; R Timothy Bentley; Rebecca A Packer; Matthew Breen; C Elizabeth Boudreau; Jonathan M Levine; R Mark Simpson; Charles Halsey; William Kisseberth; John H Rossmeisl; Peter J Dickinson; Timothy M Fan; Kara Corps; Kenneth Aldape; Vinay Puduvalli; G Elizabeth Pluhar; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-05-14       Impact factor: 12.300

9.  C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.

Authors:  Prit Benny Malgulwar; Aruna Nambirajan; Pankaj Pathak; Mohammed Faruq; Madhu Rajeshwari; Manmohan Singh; Vaishali Suri; Chitra Sarkar; Mehar Chand Sharma
Journal:  J Neurooncol       Date:  2018-01-22       Impact factor: 4.130

Review 10.  Biology and management of ependymomas.

Authors:  Jing Wu; Terri S Armstrong; Mark R Gilbert
Journal:  Neuro Oncol       Date:  2016-03-28       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.